Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control

Executive Summary

With an array of high quality drugs and preference for stacked combo therapy in multiple myeloma, the disease is poised to become a testing ground for cost containment in oncology.


Related Content

Oncology Combo Drugs Face UK Market Access Disappointment
Tagrisso Funding Journey Shows UK’s Revamped Cancer Drugs Fund Is No Soft Touch
Amgen's Kyprolis Miss In First-Line Myeloma Surprising, But Clinically Irrelevant
Another Sea Change In Myeloma Promised By New Therapies, Combos
Myeloma Drug Access Limits Unlikely Near-term – Aetna, Express Scripts Say
ICER Questions Cost Effectiveness Of Empliciti, Kyprolis, Ninlaro
Multiple Myeloma Market Snapshot: New Drugs And Big Changes
Emergence Of New Myeloma Drugs, And Combinations, Raises Red Flag On Costs
WellPoint Cancer Drug Pathways Program Aims To Save 4% In Annual Costs
Cancer Pathways Will Help Inform Drug Performance Measures, Payers Say


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts